Guardant Health Leads the Way in Blood-Based Single Cancer Screening
As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.
Hosted on MSN35m
Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More
This week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The ...
JD Supra44m
FDA Layoffs, RFK Jr. at HHS, and What This Means for FDA-Regulated Companies
In recent weeks, the FDA has faced significant cuts, including the layoffs of probationary employees. These employees, many ...